[1]李强,刘峰,陈硕,等.非酒精性脂肪性肝病诊疗进展及健康管理策略[J].慢性病学杂志,2019,20(05):637-640.
点击复制
非酒精性脂肪性肝病诊疗进展及健康管理策略(PDF)
《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]
- 卷:
- 20
- 期数:
- 2019年05期
- 页码:
- 637-640
- 栏目:
- 述 评
- 出版日期:
- 2019-05-28
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- R575
- DOI:
- -
- 摘要:
- 非酒精性脂肪性肝病（non-alcoholic fatty liver disease，NAFLD）包括非酒精性脂肪肝、非酒精性脂肪 性肝炎及其相关肝硬化和肝细胞癌，是21世纪全球重要的公共健康问题。为规范内科医师和预防保健人员对 NAFLD诊断和治疗，自2010年以来，中国、欧洲、美国等国家的肝病学会相继出版了《非酒精性脂肪性肝病诊 疗指南》和《脂肪性肝病诊疗规范化专家建议》。2011年，中华中医药学会脾胃病分会出版了《非酒精性脂肪肝 病中医诊疗共识意见》。这些指南或专家建议从临床医疗机构职能出发，能够帮助临床医师对门诊患者中NAFLD 的诊断和治疗做出正确决策。健康体检人群中NAFLD患病率为15%~30%，随着健康体检人群规模越来越大， 体检机构每年筛查出大量的NALFD。由于缺乏适宜的NAFLD健康管理模式，NAFLD人群未得到有效的管 理。此外，由于健康宣教不足，绝大多数体检人群对NAFLD的危害认识不够，大量的NAFLD人群仍然未去医 院就诊，分散在社会中。本文从健康管理实际出发，探讨NAFLD的健康管理策略。
- Abstract:
- -
参考文献/References:
[1] Farrell GC, Larter CZ. Nonalcoholic fatty liver disease:
from steatosis to cirrhosis [J]. J Hepatol, 2006,43(2 Suppl
1):S99-S112.
[2] de Alwis NM, Day CP. Non-alcoholic fatty liver disease:
the mist gradually clears [J]. J Hepatol, 2008,48(Suppl 1):
S104-S112.
[3] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty
liver disease in China [J]. J Hepatol, 2009,50(1):204-210.
[4] 中华医学会健康管理学分会,中华健康管理学杂志编委会.健康
管理概念与学科体系的中国专家初步共识[J].中华健康管理学杂
志,2009,3:141-147.
[5] Angulo P. GI epidemiology: nonalcoholic fatty liver disease
[J]. Aliment Pharmacol Ther, 2007,25(8):883-889.
[6] Fan JG, Saibara T, Chitturi S,et al. What are the risk
factors and settings of non-alcoholic fatty liver disease in
Asia Pacific [J]. J Gastroenterol Hepatol,2007,22(6):794-800.
[7] Wei J, Rau M, Geier A. Non-Alcoholic Fatty Liver Dis-ease: Epidemiology，Clinical Course, Investigation, and
Treatment [J]. Deutsches Rzteblatt International,2014,111
(26):447-452.
[8] 蒋正,申振伟,张光,等.基于体检人群的非酒精性脂肪肝筛查工具的建立[J].山东大学学报,2017,55(6):114-118.
[9] Cheung O, Sanyal AJ. Hepatitis C infection and nonalco-holic fatty liver disease [J]. Clin Liver Dis, 2008,12(3):
573-585.
[10] Bram B, Hesselink MKC, Patrick S,et al. Effects of ex-ercise training on intrahepatic lipid content in humans [J].
Diabetologia,2016,59(10):2068-2079.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会
脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018年
更新版）[J].实用肝脏病杂志,2018,21(2):177-186.
[12] European Association for the Study of the Liver (EASL);
European Association for the Study of Diabetes (EASD);
European Association for the Study of Obesity (EASO).
EASL-EASD-EASO Clinical Practice Guidelines for the
management of non-alcoholic fatty liver disease [J]. J Hep-atol, 2016,64(6):1388-1402.
[13] Chalasani N, Younossi Z, Lavine JE,et al. The diagno-sis and management of nonalcoholic fatty liver disease:
Practice guidance from the American Association for the
Study of Liver Diseases [J]. Hepatol,2017,67(1):328-357.
[14] 中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化专
家建议[J].中国实用内科杂志,2013,33(7):525-529.
[15] 范建高,曾民德.脂肪性肝病[M].2版.北京:人民卫生出版社,
2013.
[16] Bedossa P, FLIP Pathology Consortium. Utility and ap-propriateness of the fatty liver inhibition of progression
(FLIP) algorithm and steatosis, activity, and fibrosis
(SAF) score in the evaluation of biopsies of nonalcoholic
fatty liver disease [J]. Hepatol, 2014,60(2):565-575.
[17] Vos MB, Abrams SH, Barlow SE,et al. NASPGHAN
Clinical Practice Guideline for the diagnosis and treatment
of nonalcoholic fatty liver disease in children: Recommen-dations from the Expert Committee on NAFLD (ECON)
and the North American Society of Pediatric Gastroenterol-ogy，Hepatology and Nutrition (NASPGHAN) [J]. J Pediatr
Gastroenterol Nutr,2017,64(2):319-334.
[18] 信丰智,范建高.欧洲非酒精性脂肪性肝病诊疗指南简介[J].实用
肝脏病杂志,2016,19(4):Ⅶ-Ⅷ.
[19] 石翠翠,范建高.美国非酒精性脂肪性肝病诊疗指南解读[J].实用
肝脏病杂志,2017,20(5):Ⅳ-Ⅵ.
[20] 曾静,范建高.北美儿童非酒精性脂肪性肝病诊疗指南简介[J].实
用肝脏病杂志,2017,20(5):Ⅸ-Ⅹ.
[21] 王琴,魏来.国内外儿童与成人非酒精性脂肪性肝病诊疗指南的
比较与解析[J].临床肝胆病杂志,2017,33(12):2265-2269.
[22] 范建高.国内外非酒精性脂肪性肝病诊疗指南的异同[J].临床肝
胆病杂志,2012,28(7):493-495.
[23] Stepanova M, Younossi ZM. Independent association be-tween nonalcoholic fatty liver disease and cardiovascular
disease in the US population [J]. Clin Gastroenterol Hepa-tol, 2012,10(6):646-650.
[24] Park HE, Kwak MS, Kim D, et al. Nonalcoholic fatty
liver disease is associated with coronary artery calcification
development: a longitudinal study [J]. J Clin Endocrinol
Metab,2016,101(8):3134-3143.
[25] Kim BJ, Kim NH, Kim BS,et al. The association be-tween nonalcoholic fatty liver disease, metabolic syndrome
and arterial stiffness in nondiabetic, nonhypertensive indi-viduals [J]. Cardiol,2012,123(1):54-61.
[26] Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver dis-ease and nonalcoholic steatohepatitis: Selected practical is-sues in their evaluation and management [J]. Hepatol,
2009,49(1):306-317.
[27] Fan JG. Impact of non-alcoholic fatty liver disease on ac-celerated metabolic complications [J]. J Dig Dis, 2008,9(2):
63-67.
[28] European Association for Study of Liver, Asociacion Lati-noamericana parael Estudio del Higado. EASL-ALEH Clinical
Practice Guidelines: Non- invasive tests for evaluation of
liver disease severity and prognosis [J]. J Hepatol, 2015,63
(1):237-264.
[29] Shen F, Zheng RD, Shi JP,et al. Impact of skin capsu-lar distance on the performance of controlled attenuation
parameter in patients with chronic liver disease [J]. Liver
Int, 2015,35(11):2392-2400.
[30] Kwok R, Choi KC, Wong GL,et al. Screening diabetic
patients for non- alcoholic fatty liver disease with con-trolled attenuation parameter and liver stiffness measure-ments: a prospective cohort study [J]. Gut,2016,65(8):
1359-1368.
[31] Chitturi S, Wong VW, Chan WK,et al. The Asia-Pacif-ic Working Party on Non- alcoholic Fatty Liver Disease
guidelines 2017- Part 2: Management and special groups
[J]. J Gastroenterol Hepatol, 2018,33(1):86-98.
[32] 曾静,孙婉璐,陈光榆,等.FibroTouch与FibroScan肝脏硬度和
脂肪定量检测效能的比较[J].中华肝脏病杂志,2016,24(9):652-658.
[33] Bellentani S. The epidemiology of non-alcoholic fatty liver
disease [J]. Dig Dis,2017,28(1):155-161.
[34] Zhang HJ, Pan LL, Ma ZM, et al. Long-term effect of
exercise on improving fatty liver and cardiovascular risk
factors in obese adults: A 1-year follow-up study [J]. Dia-betes Obes Metab,2017,19(2):284-289.
[35] Bram B, Hesselink MKC, Patrick S,et al. Effects of ex-ercise training on intrahepatic lipid content in humans [J].
Diabetologia,2016,59(10):2068-2079.
[36] Zhang HJ, He J, Pan LL,et al. Effects of Moderate and
Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A
Randomized Clinical Trial [J]. JAMA Intern Med,2016,
176(8):1074-1082.
收稿日期：2019-02-25修回日期：2019-04-15
备注/Memo
- 备注/Memo:
- 基金项目：北京市体检中心科研专项基金（BJTJ-2018-05） 作者简介：李强，研究生，副研究员，研究方向：慢性病 防控研究 通信作者：张静波，E-mail：13910625118@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed768
- 全文下载/Downloads682
- 评论/Comments
